British Society for Integrative Oncology’s Post

📢 PH updates from the ESC Congress 2024 in London! 🌟 This year's European Society of Cardiology Congress 2024 highlighted the continued focus on pulmonary hypertension (PH), featuring sessions like "Current Pharmacological Treatments for Pulmonary Hypertension," "Chronic Thromboembolic Pulmonary Hypertension: Is It Worth Learning About?" and "Shaping the Future Management of Pulmonary Hypertension." These discussions underscored the progress being made in the field and the ongoing commitment to improving patient care. There is growing excitement around new medications entering the market and numerous ongoing trials, and the emphasis on integrating patient perspectives into clinical trials and guidelines marks an important shift. The inclusion of Patient-Reported Outcome Measures (PROMs) is essential to ensuring that treatments align with the real-world needs and experiences of patients. Additionally, advocating for early patient involvement in the drug research process remains a key priority. Let’s continue to push for patient-centered research and make sure our voices are heard every step of the way. The recent developments showcased at WSPH 2024 and ESC 2024 represent a significant step forward, promising a brighter future for all PH patients worldwide! 💪❤️ Learn more about our initative: www.phaeurope.org #ESC2024 #PulmonaryHypertension #PatientAdvocacy #Cardiology #MedicalResearch #FutureOfMedicine #PROMs Hipertensión Pulmonar Argentina PH Belgium - Pulmonale Hypertensie vzw Hipertensión Pulmonar España ORG Pacientes Fundación Contra la Hipertensión Pulmonar Asociación Nacional de Hipertensión Pulmonar ANHP Stichting Pulmonale Hypertensie / PH Association the Netherlands PH Serbia AIPI Italian Pulmonary Hypertension Association Fundación Ayúdanos a Respirar Sociedad Latina de Hipertensión Pulmonar HAPCHI Asociacion Chilena de Hipertension Pulmonar Pulmonary Hypertension Association of South Africa

Elevate ↗️ your understanding regarding ventilation strategies 🌬️ in Cardiogenic Shock 🫀 Once again, a must-read article🤓 for a better understanding of ventilation issues in patients suffering cardiogenic shock ‼️

Published this week: exciting news from the SoLVE Study! The results are in, shedding light on optimal treatment approaches for severe COPD patients who are scheduled to undergo a bronchoscopic lung volume reduction using Zephyr (Pulmonx Corporation) one-way endobronchial valves.   The multicenter SoLVE Study (NCT03474471), conducted at UMC-Groningen (Sonja Augustijn, Marieke van der Molen, Jorine Hartman, David Koster, Marlies van Dijk, Hester Van der Vaart, Karin Klooster, and Dirk-Jan Slebos) and Maastricht-UMC+/CIRO (Rein Posthuma, Martijn Spruit, Anouk Vaes, and Lowie Vanfleteren) in collaboration with the Dutch pulmonary rehab-centers, and funded by the Dutch lung foundation (Longfonds), investigated the combination of valve treatment and pulmonary rehabilitation. Previously, it was recommended that patients undergo pulmonary rehabilitation before valve treatment, but this had not been thoroughly studied. Another hypothesis suggested that post-valve treatment rehabilitation might offer additional benefits due to reduced lung hyperinflation, potentially enabling higher exercise capacity. Our randomized study involved 97 patients assigned to three groups: rehabilitation before valve treatment, rehabilitation after valve treatment, or valve treatment alone. After six months, no significant differences were found in outcomes, including exercise capacity, lung function, physical activity, muscle function, body composition, and quality of life, regardless of whether patients underwent rehabilitation. These findings suggest that pulmonary rehabilitation may not be a prerequisite for patients undergoing valve treatment. However, identifying patients who would benefit most from a combined treatment approach remains a challenge for the future.   You can find the entire article here: https://lnkd.in/ebVFHxcr   Stay tuned for more insights as we continue to refine care strategies for individuals with lung conditions! #COPD #Emphysema #Bronchoscopy #PulmonaryRehabilitation #Endobronchialvalves #Lungvolumereduction

Breathing new life: how research collaborations enhance patient care 💡 A collaboration between Aarhus University Hospital and Aalborg University Hospital between doctors Mads Bøgh, Søren Gade, Dalia Gustaityté Larsen, Sten Schytte, Ulrik Pedersen, and Thomas Kjærgaard resulted in new knowledge about silicone stents in airway obstruction care for cancer patients 🏥 🧐 The team studied 81 patients who received silicone stents between 2012 and 2022 to relieve severe airway blockages caused by cancer. They aimed to evaluate how these stents affected breathing, quality of life, and overall survival. ❗ The findings showed that while silicone stents provided symptom relief for 95% of patients, the overall survival rate remained low, with an average of 158 days. Complications occurred in 25.6% of cases, and factors such as urgent intervention and preprocedural respiratory support were associated with poorer outcomes. However, post-procedural cancer treatment was linked to improved results. 👨⚕️ The study collaboration highlights the effectiveness of silicone stents in alleviating symptoms for cancer patients but also emphasizes the need for further research to identify predictors of better outcomes and enhance patient care. Hospital collaboration improves data quality, diversifies perspectives, and enables knowledge sharing. By combining resources, hospitals can develop advanced technologies and expertise, ensuring patients receive the most effective and up-to-date care available. ➡️ Read the full article here (open access): https://lnkd.in/dzWbV8J3 #Collaboration #SiliconeStents #Cancer #QualityOfLife #ENT #AalborgUH #AarhusUH

At this year's European Society of Cardiology (ESC) Congress, Bayer unveiled late-breaking results from the Phase III FINEARTS-HF trial, showcasing the efficacy of KERENDIA® (finerenone) in patients with heart failure (HF). The trial's focal point was those with left ventricular ejection fraction (LVEF) of 40% or higher ✅ The FINEARTS-HF trial involved around 6,000 patients, with results indicating a significant reduction in cardiovascular deaths and total HF events. This breakthrough not only confirms finerenone's potential but also highlights its benefits for a broad range of patients, extending beyond those with chronic kidney disease and type 2 diabetes. 📊 Key Findings: - 🗸 Statistically significant reductions in cardiovascular death and HF events - 🗸 Benefits observed for HF patients with LVEF ≥40%, irrespective of CKD/T2D status - 🗸 Enhances the clinical landscape for HF management Bayer's presentation also included data from the FINE-HEART study, integrating results from three major trials. This comprehensive analysis underscores finerenone's promise in improving cardio-kidney outcomes. Additionally, attention was given to the OCEANIC-AF trial, investigating the anticoagulant asundexian in patients with atrial fibrillation (pending approval). #EuropeanSocietyofCardiology #HeartFailure #Cardiology #ClinicalTrials #ClinicalResearch #Bayer #LifeScience #StaffingPartner #ElixirAssociates

https://lnkd.in/gmTPCR5i Article title: The pathophysiology of chronic cardiorenal disease based on central hemodynamics Author(s): Michiya Ohno* Journal: Journal of Cardiovascular Medicine and Cardiology Journal ISSN: 2455-2976 Abstract: As patients with chronic kidney disease (CKD) and chronic heart failure (CHF) increase, there is concern about a future heart failure pandemic. Deterioration of renal function is an independent prognostic factor for CHF after decongestion. Interactions between renal disease and cardiac disease are increasing, including nephrosclerosis and heart failure with preserved ejection fraction (HFpEF), which are both derived from augmentation of central pulse pressure by age-related arterial stiffening. Thus, it is necessary to treat multiple underlying diseases of cardiorenal syndrome simultaneously. However, an effective therapeutic strategy for HFpEF has not been established. This review reconsiders the pathophysiology of chronic cardiorenal disease related to arterial stiffening from the viewpoint of central hemodynamics and explores treatment options. #CentralBloodPressure #CardiorenalSyndrome #HFpEF #HeartFailureWithPreservedEjectionFraction #VentricularArterialStiffening #CoronaryArteryDiseases #ValvularHeartDisease #Electrophysiology #CardiacElectrophysiology #Echocardiography #InterventionalCardiology #ClinicalCardiology #NuclearCardiology #AcuteCoronarySyndromes #ArrhythmiaEP #CVImaging #CVDPrevention #CardiacArrhythmias #Peertechz #PeertechzPublications #OpenAccess #ScientificJournals #PeerReviewedJournals #OpenAccessPublishers #CardiacPhysiology #CardiacRegeneration #CardiacRehabilitation #Cardiomyopathies #CardiovascularDrugs #CardiovascularTherapy #CardiovascularAnatomy #CongenitalHeartDefects 

Clinicians at King's College Hospital NHS Foundation Trust are leading the way in exploring a first-of-its-kind treatment for aplastic anaemia (AA) using cell therapy through the TIARA trial. Initial phase 1 results from the trial are promising, offering new hope to people living with AA. 🔗 https://lnkd.in/e7RiKZen AA is a rare and life-threatening condition where the bone marrow fails to produce enough blood cells, causing severe fatigue, infections, and bleeding risks. Current treatments, such as immune-suppressive therapy or stem cell transplants, are often insufficient or unsuitable for many patients. The trial is made possible through our collaboration with The Aplastic Anaemia Trust. Managed by King's Health Partners Haematology, this initiative brings together the expertise of 3 NHS Foundation Trusts in London with the academic prowess of King's College London. The TIARA trial represents a critical step forward in advancing patient care, potentially providing a better chance of survival and an improved quality of life. Video courtesy of King's College London. #AplasticAnaemia #RareDisease #LifeScienceResearch

https://lnkd.in/guW_HPBV Article title: Lactate Dehydrogenase is involved in but not the Target Antigen in Children with Kawasaki Disease Author(s): Lanqing Zhao; Chunna Zhao; Zhongdong Du; Hongwu Du Journal: Journal of Cardiovascular Medicine and Cardiology Journal ISSN: 2455-2976 Abstract: Background: Kawasaki disease (KD) is an acute vasculitis often complicating coronary arterial lesions, and gradually becomes the leading cause of acquired heart disease instead of rheumatism. Previous studies often regards elevation of serum lactate dehydrogenase (LDH) level as an auxiliary diagnosis marker when judging myocardial diseases. Methods: We analyzed the serum LDH levels in newly confirmed KD patients, compared with febrile non-KD patients and healthy donors as controls. Then a subtype of LDH protein (LDHA) were over-expressed and purified for antigenicity analysis of potential anti-LDHA autoantibodies in IgA, IgM and IgG isotype by homemade ELISA, respectively. #LactateDehydrogenase #KawasakiDisease #ExpressionAndPurification #AntigenicityAnalysis #AutoimmuneTarget #CoronaryArteryDiseases #ValvularHeartDisease #Electrophysiology #CardiacElectrophysiology #Echocardiography #InterventionalCardiology #ClinicalCardiology #NuclearCardiology #AcuteCoronarySyndromes #ArrhythmiaEP #CVImaging #CVDPrevention #CardiacArrhythmias #Peertechz #PeertechzPublications #OpenAccess #ScientificJournals #PeerReviewedJournals #OpenAccessPublishers #CardiacPhysiology #CardiacRegeneration #CardiacRehabilitation #Cardiomyopathies #CardiovascularDrugs #CardiovascularTherapy #CardiovascularAnatomy #CongenitalHeartDefects 

Register NOW to attend this webinar today! Diagnostic Challenges and Opportunities in Alzheimer’s Disease Management, hosted by the NAMCP Medical Directors Institute   Tuesday, Sept. 17 1-2 p.m. ET; Noon-1 p.m. CT Registration is available free of charge at: https://lnkd.in/eN8JH2NF Approximately 16 million Americans are living with mild cognitive impairment and dementia and warrant a diagnostic evaluation to determine the cause of their cognitive decline. Accurate and timely detection of Alzheimer’s disease (AD) pathology in affected patients continues to be a significant hurdle to delivering optimal care for patients with signs and symptoms of cognitive decline. There is an urgent unmet need for safe, lower cost, less resource-intensive, easily accessible, and broadly available tests that identify the presence or absence of brain amyloid plaques, a pathological hallmark of AD. Current care may be improved using high performing blood biomarkers to potentially shorten the diagnostic journey and facilitate the early treatment of Alzheimer’s disease. Speakers: Ian Kremer, JD, Executive Director, LEAD (Leaders Engaged on Alzheimer's Disease) Coalition Suzanne Schindler, MD, PhD, Associate Professor of Neurology, Washington University School of Medicine in St. Louis Joel Braunstein, MD, MBA, CEO and Co-Founder, C2N Diagnostics, LLC Learning Objectives: 1. Understand the value of early diagnosis in the care management of patients with cognitive impairment 2. Recognize the usual clinical care pathway for the evaluation of patients with cognitive impairment and new expert recommendations and appropriate use criteria on care management 3. Analyze the differences between different biomarker tests for brain amyloid and their approaches for helping clinicians diagnose Alzheimer’s disease 4. Evaluate the opportunity for a high-accuracy blood biomarker test to streamline diagnosis and management strategies https://lnkd.in/eN8JH2NF #webinar #Alzheimers #Alzheimersdisease #precisionmedicine #bloodbiomarkers #diagnosis

Tomorrow (Sept. 17) don’t miss this important webinar hosted by NAMCP (National Association of Managed Care Physicians) on blood biomarkers that should be of keen interest to healthcare providers and administrators, payors, lab directors, and other key stakeholders: Diagnostic Challenges and Opportunities in Alzheimer’s Disease Management Registration is available free of charge at: https://lnkd.in/eN8JH2NF   Tuesday, Sept. 17 1-2 p.m. ET; Noon-1 p.m. CT Approximately 16 million Americans are living with mild cognitive impairment and dementia and warrant a diagnostic evaluation to determine the cause of their cognitive decline. Accurate and timely detection of Alzheimer’s disease (AD) pathology in affected patients continues to be a significant hurdle to delivering optimal care for patients with signs and symptoms of cognitive decline. There is an urgent unmet need for safe, lower cost, less resource-intensive, easily accessible, and broadly available tests that identify the presence or absence of brain amyloid plaques, a pathological hallmark of AD. Current care may be improved using high performing blood biomarkers to potentially shorten the diagnostic journey and facilitate the early treatment of Alzheimer’s disease. Speakers: Ian Kremer, JD, Executive Director, LEAD (Leaders Engaged on Alzheimer's Disease) Coalition Suzanne Schindler, MD, PhD, Associate Professor of Neurology, Washington University School of Medicine in St. Louis Joel Braunstein, MD, MBA, CEO and Co-Founder, C2N Diagnostics, LLC Learning Objectives: 1. Understand the value of early diagnosis in the care management of patients with cognitive impairment 2. Recognize the usual clinical care pathway for the evaluation of patients with cognitive impairment and new expert recommendations and appropriate use criteria on care management 3. Analyze the differences between different biomarker tests for brain amyloid and their approaches for helping clinicians diagnose Alzheimer’s disease 4. Evaluate the opportunity for a high-accuracy blood biomarker test to streamline diagnosis and management strategies #webinar #Alzheimers #Alzheimersdisease #precisionmedicine #bloodbiomarkers #diagnosis #NAMCP